eteplirsen
Selected indexed studies
- Eteplirsen. (, 2012) [PMID:32223120]
- Eteplirsen for the treatment of Duchenne muscular dystrophy. (Ann Neurol, 2013) [PMID:23907995]
- Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial. (J Neuromuscul Dis, 2021) [PMID:34120909]
_Worker-drafted node — pending editorial review._
Connections
eteplirsen is a side effect of
Sources
- Eteplirsen. (2012) pubmed
- Eteplirsen for the treatment of Duchenne muscular dystrophy. (2013) pubmed
- Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial. (2021) pubmed
- Eteplirsen: First Global Approval. (2016) pubmed
- Eteplirsen in the treatment of Duchenne muscular dystrophy. (2017) pubmed
- Eteplirsen Treatment for Duchenne Muscular Dystrophy: A Qualitative Patient Experience Study. (2024) pubmed
- Eteplirsen for paediatric patients with Duchenne muscular dystrophy: A pooled-analysis. (2018) pubmed
- Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update. (2022) pubmed
- Survival in eteplirsen-treated Duchenne Muscular Dystrophy patients: Are there benefits beyond steroids? (2024) pubmed
- Eteplirsen. (2017) pubmed